Company Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company was incorporated in 1987 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jan 22, 1992 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 18,000 |
| CEO | Daniel P. O'Day |
Contact Details
Address: 333 Lakeside Dr Foster City, California 94404 United States | |
| Phone | (650) 574-3000 |
| Website | gilead.com |
Stock Details
| Ticker Symbol | GILD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882095 |
| CUSIP Number | 375558103 |
| ISIN Number | US3755581036 |
| Employer ID | 94-3047598 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel P. O'Day | Chairman and Chief Executive Officer |
| Andrew D. Dickinson | Chief Financial Officer |
| Deborah H. Telman | Executive Vice President of Corporate Affairs, General Counsel and Corporate Secretary |
| Johanna Mercier | Chief Commercial Officer |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer |
| Sandra Patterson | Senior Vice President, Corporate Controller and Principal Accounting Officer |
| Jacquie Ross C.F.A. | Vice President of Investor Relations |
| Jyoti K. Mehra | Executive Vice President of Human Resources |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation and Portfolio |
| Dr. Rudolf Ertl | Senior Vice President of Commercial Operations of Australia, Canada, Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 3 | Initial statement of beneficial ownership of securities |
| Apr 3, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Apr 3, 2024 | 3 | Initial statement of beneficial ownership of securities |
| Apr 1, 2024 | 144 | Filing |
| Mar 28, 2024 | ARS | Filing |
| Mar 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 18, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 14, 2024 | 8-K | Current Report |